Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin in Vascular Dementia
NCT00947531Phase 4Completed
- Sponsor
- EVER Pharma
- Start
- Oct 2006
- Modality
- Native Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in vascular dementia comparing Cerebrolysin with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive Subpart at 24 weeks and Clinicians Interview-based Impression of Change at 24 weeks. Started Oct 2006; status: completed.
02
Drugs
cerebrolysin
03
Conditions
vascular dementia
Beyond the preview
Go deeper on NCT00947531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00947531.